ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

ASCO proposes compromise to limit payment cuts proposed by Congress, CMS.

September 12, 2003

Study Begins On Link Between Down Syndrome, Leukemia

May 28, 2004

Obit: Former Roswell Park Director Gerald Murphy, 65, In Tel Aviv.

January 28, 2000

Group Chairs: Research In “Crisis” ASCO Says NCTN Budgets Cut By 40 Percent, Warns of “Dangerous Disruption of Cancer Care”

April 4, 2014

In Brief: NIDR, NCI award $2.8 Million In Grants For Oral Cancer research Centers

October 4, 1996

Robert Cook-Deegan’s Viewers’ Guide To the Super Bowl of Gene Patent Cases

March 14, 2014